使用存活年−年代−世代模型預測臺灣肺癌存活率至2025年

Predicting Lung Cancer Survival in Taiwan to 2025 Using the Survivorship-Period-Cohort model

孟繁璀(Fan-Tsui Meng)

指導教授 ： 李文宗

國立臺灣大學/公共衛生學院/流行病學與預防醫學研究所/碩士(2022年)

https://doi.org/10.6342/NTU202202832

摘要

肺癌是所有癌症中死亡率最高的。為提高肺癌存活率，國際肺癌防治聯盟-肺志氣聯盟揭櫫於2025年將肺癌5年存活率翻倍的目標。本研究使用臺灣癌症登記中心1997年7月至2018年6月的肺癌資料，利用存活年-年代-世代模型進行臺灣肺癌患者存活率之未來預測。我們發現臺灣肺癌存活率在2004診斷年之前下降，此後上升。至2025年，肺癌五年存活率將從目前的23.8%提升至38.7%，增加絕對量為14.9%，提升倍率為1.6倍。肺癌存活率2004年後上升與標靶藥物和正子斷層造影納入健保給付的時間點相吻合。低劑量電腦斷層掃描肺癌篩檢亦有助益肺癌存活率的上升。

關鍵字

肺癌 ； 存活率 ； 存活年−年代−世代模型 ； 預測 ； 長期趨勢

並列摘要

Lung cancer has the highest mortality rate of all cancers. To improve the survival rate of lung cancer, the global lung cancer prevention alliance-Lung Ambition Alliance announced the goal of doubling the 5-year survival of lung cancer by 2025. We used lung cancer data from the Taiwan Cancer Registry from July 1997 to June 2018, and we predicted the future survival of lung cancer patients in Taiwan using the survivorship-period-cohort model. We found that the survival for lung cancer in Taiwan decreased before 2004 year of diagnosis and increased after that. By 2025, the 5-year survival of lung cancer will increase from 23.8% to 38.7%, an absolute increase of 14.9%, and a 1.6-fold increase. The increase in survival after 2004 coincided with when National Health Insurance paid for the targeted drugs and positron emission tomography. Lung cancer screening with low-dose computed tomography has also improved lung cancer survival.

並列關鍵字

lung cancer ； survival ； survivorship-period-cohort model ； prediction ； long-term trend

參考文獻

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.

De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R, EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5−a population-based study. Lancet Oncol. 2014;15(1):23-34.

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017;109(9):djx030.

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, E Silva GA, Chen W, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP, CONCORD Working Group. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075.